GlassScriptPhysician profile
Rishi Basnyat
NPI 1609158799
$1,531.36
in general payments reported to CMS, 2019-2025
14 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $85.93 · 2024: $164 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.89 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.04 | 2025 | Wegovy, Ozempic |
| Corcept Therapeutics | $185.32 | 2025 | Korlym |
| Abbott Laboratories | $160.26 | 2022 | |
| Inspire Medical Systems, INC. | $157.89 | 2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $145.04 | 2025 | Terlivaz |
| Gilead Sciences, INC. | $125.00 | 2024 | Veklury |
| Neurelis, INC. | $124.98 | 2025 | Valtoco |
| Lilly USA, LLC | $120.86 | 2025 | Kisunla |
| Boston Scientific Corporation | $85.93 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $44.37 | 2025 | |
| Exact Sciences Corporation | $26.54 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $14.96 | 2025 | Dupixent |
| Abbvie INC. | $13.51 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.66 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Basnyat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.